Archives
-
Targeted Amikacin Delivery into Mycobacterial Granulomas
2026-09-26
The study tested whether dendritic cells could carry fluorescently labeled amikacin into Mycobacterium avium granulomas in mice, addressing the challenge of reaching organisms sequestered in infected tissue. The findings support targeted delivery as a preclinical approach, but establish localization rather than improved infection control or clinical benefit.
-
ATRX Loss and RTK Inhibitor Sensitivity in Glioma
2026-09-25
A drug screen reported that ATRX-deficient high-grade glioma cells were more sensitive to several multi-targeted receptor tyrosine kinase inhibitors and platelet-derived growth factor receptor inhibitors than ATRX-proficient comparators. The study also found pronounced toxicity with combined RTK-inhibitor and temozolomide treatment in ATRX-deficient cells, supporting ATRX status as a biomarker to evaluate in further preclinical and clinical research—not as a proven treatment-selection rule.
-
Nullscript and Placental Ferroptosis: A Research Framework
2026-09-25
Nullscript is a histone deacetylase inhibitor with a distinctive transcriptional profile. This article connects its established research context to a placental nanoplastic study—and explains how to test that cross-domain hypothesis without mistaking a useful experimental probe for an established treatment.
-
GOB-38 in E. anophelis: Activity and Substrate Range
2026-09-24
The study characterizes GOB-38, a metallo-β-lactamase from Elizabethkingia anophelis, and reports activity across penicillins, cephalosporins, and carbapenems. Its biochemical findings, together with clinical co-isolation and co-culture experiments, highlight questions about resistance in mixed infections while leaving the mechanism and extent of any interspecies transfer to be resolved.
-
Cefepime in Plasmid-Mediated Resistance Research
2026-09-24
Cefepime (BMY-28142) can help researchers examine how mobile resistance genes reshape beta-lactam susceptibility. This article interprets recent Enterobacter cloacae transmission findings as practical guidance for building more informative genotype–phenotype assays.
-
Hyperforin Activates Dlat–Trpv3 Adipose Thermogenesis
2026-09-23
A 2025 study reports that hyperforin promotes adipose thermogenesis through a Dlat-dependent Trpv3–calcium–Camkkb–AMPK pathway, providing a mechanistic alternative to canonical β3-adrenergic signaling. Mouse, cell-based, and pharmacokinetic experiments support further investigation, while leaving human efficacy and long-term safety unresolved.
-
Fumagillin Workflows for Angiogenesis Research
2026-09-23
Fumagillin is a mechanistically defined methionine aminopeptidase-2 inhibitor for connecting endothelial cell assays with pathogen-focused screening. This practical guide emphasizes fresh solution handling, evidence-aligned dose finding, comparative controls, and the limits of translating aquatic parasite results into cancer research.
-
T0070907 as a Causal PPARγ Signaling Probe
2026-09-22
T0070907 is a high-affinity PPARγ antagonist for dissecting receptor-dependent transcription, adipogenesis, inflammatory aging, and cancer-cell cycle responses. This article translates RXRα/PPARγ/NEDD4 findings into a rigorous experimental framework that separates pathway causality from downstream correlation.
-
Brefeldin A: Turning Trafficking Stress into Insight
2026-09-22
Brefeldin A is more than a vesicle transport inhibitor: it is a mechanistic probe for connecting ER–Golgi disruption with protein quality control, ER stress, and cancer-cell fate. This article outlines how to use BFA strategically in translational research while separating established evidence from testable hypotheses.
-
Sodium Citrate in 3D SERS Workflows
2026-09-21
Sodium citrate supports controlled pH and metal-ion management, while polymer pen lithography determines the geometry and reproducibility of 3D gold nanocluster SERS substrates. This practical guide separates validated product functions from study-derived findings and provides a control-first workflow for qualification, troubleshooting, and assay optimization.
-
Mitocytosis Targeting Enhances Mitochondrial Therapy
2026-09-21
Deng and colleagues identify mitocytosis as a resistance mechanism that limits mitochondria-targeted antimetastatic therapy in migrasome-rich tumors. Their hybrid membrane nanoplatform combines mitochondrial damage with integrin-mediated mitocytosis inhibition, providing a strategy to improve therapeutic activity in the 4T1 breast tumor model.
-
Streptavidin – Cy5 in Apoptosis Assays
2026-09-20
Learn how Streptavidin – Cy5 converts biotinylated antibodies, probes, and proteins into a flexible far-red readout for breast cancer apoptosis workflows. This guide connects the USP42–JNK/p38 findings with practical flow cytometry, immunofluorescence, immunohistochemistry, and troubleshooting strategies.
-
O6-Benzylguanine: A Functional MGMT Inhibitor
2026-09-19
O6-Benzylguanine is a potent MGMT inhibitor for dissecting DNA repair inhibition and sensitization to alkylating agents. This article presents an assay-centered framework that connects direct MGMT inactivation with the transcriptional findings reported in recurrent glioblastoma research.
-
Immunodominant B-Cell Epitopes for P. vivax
2026-09-18
This 2026 study combines computational antigen prioritization, peptide serology, multiplex validation, and conservation analysis to identify species-specific Plasmodium vivax B-cell epitopes. Four candidates showed strong diagnostic performance, while MSP9₃₈₄–₃₈₉ provided a potentially useful signal for identifying asymptomatic infections and hidden transmission reservoirs.
-
Mianserin HCl: Applied Research Workflows
2026-09-18
Mianserin HCl gives researchers a practical way to probe noradrenergic and serotonergic signaling while separating receptor effects from exposure and tolerability. This guide translates clinical-trial logic into cell, receptor, cyclodextrin, and antipathogenic workflows with actionable optimization advice.